Archive for October 1, 2016

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method

European Respiratory Journal Oct 2016 v.48 N.4 P.1160-1170

Carole D. Mitnick, Richard A. White, Chunling Lu, Carly A. Rodriguez, Jaime Bayona, Mercedes C. Becerra, Marcos Burgos, Rosella Centis, Theodore Cohen, Helen Cox, Lia D’Ambrosio, Manfred Danilovitz, Dennis Falzon, Irina Y. Gelmanova, Maria T. Gler, Jennifer A. Grinsdale, Timothy H. Holtz, Salmaan Keshavjee, Vaira Leimane, Dick Menzies, Giovanni Battista Migliori, Meredith B. Milstein, Sergey P. Mishustin, Marcello Pagano, Maria I. Quelapio, Karen Shean, Sonya S. Shin, Arielle W. Tolman, Martha L. van der Walt, Armand Van Deun, Piret Viiklepp,  on behalf of the Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment

Debate persists about monitoring method (culture or smear) and interval (monthly or less frequently) during treatment for multidrug-resistant tuberculosis (MDR-TB). We analysed existing data and estimated the effect of monitoring strategies on timing of failure detection.

We identified studies reporting microbiological response to MDR-TB treatment and solicited individual patient data from authors. Frailty survival models were used to estimate pooled relative risk of failure detection in the last 12 months of treatment; hazard of failure using monthly culture was the reference.

Data were obtained for 5410 patients across 12 observational studies. During the last 12 months of treatment, failure detection occurred in a median of 3 months by monthly culture; failure detection was delayed by 2, 7, and 9 months relying on bimonthly culture, monthly smear and bimonthly smear, respectively. Risk (95% CI) of failure detection delay resulting from monthly smear relative to culture is 0.38 (0.34–0.42) for all patients and 0.33 (0.25–0.42) for HIV-co-infected patients.

Failure detection is delayed by reducing the sensitivity and frequency of the monitoring method. Monthly monitoring of sputum cultures from patients receiving MDR-TB treatment is recommended. Expanded laboratory capacity is needed for high-quality culture, and for smear microscopy and rapid molecular tests.



October 1, 2016 at 3:16 pm


October 2016

Posts by Month

Posts by Category